Ivax Generic Taxol Launch Could Come In June After Summary Judgment
Executive Summary
Ivax plans to launch a generic version of Bristol-Myers Squibb's Taxol (paclitaxel) without waiting for Bristol to appeal a Newark, N.J. federal court summary judgment that deems the majority of Bristol's paclitaxel patent claims invalid.
You may also be interested in...
Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents
The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings
Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents
The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings
Bristol's Taxol Appeal Emphasizes Contribution Of Improved Dosing Regimen
Bristol-Myers Squibb's Taxol patent appeal hinges in part on the company's arguments that it should receive a reward for bringing an improved dosing schedule for paclitaxel to the public.